BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Smith C, Patterson-Cross R, Woodward O, Lewis J, Chiarugi D, Merkle F, Gribble F, Reimann F, Adriaenssens A. A comparative transcriptomic analysis of glucagon-like peptide-1 receptor- and glucose-dependent insulinotropic polypeptide-expressing cells in the hypothalamus. Appetite 2022;174:106022. [PMID: 35430298 DOI: 10.1016/j.appet.2022.106022] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
Number Citing Articles
1 Boer GA, Hay DL, Tups A. Obesity pharmacotherapy: incretin action in the central nervous system. Trends Pharmacol Sci 2023;44:50-63. [PMID: 36462999 DOI: 10.1016/j.tips.2022.11.001] [Reference Citation Analysis]
2 Hammoud R, Drucker DJ. Beyond the pancreas: contrasting cardiometabolic actions of GIP and GLP1. Nat Rev Endocrinol 2022. [PMID: 36509857 DOI: 10.1038/s41574-022-00783-3] [Reference Citation Analysis]
3 Hattori Y. The Multiple Roles of Pericytes in Vascular Formation and Microglial Functions in the Brain. Life 2022;12:1835. [DOI: 10.3390/life12111835] [Reference Citation Analysis]
4 Diz-chaves Y, Mastoor Z, Spuch C, González-matías LC, Mallo F. Anti-Inflammatory Effects of GLP-1 Receptor Activation in the Brain in Neurodegenerative Diseases. IJMS 2022;23:9583. [DOI: 10.3390/ijms23179583] [Reference Citation Analysis]
5 Sango K, Takaku S, Tsukamoto M, Niimi N, Yako H. Glucagon-Like Peptide-1 Receptor Agonists as Potential Myelination-Inducible and Anti-Demyelinating Remedies. Front Cell Dev Biol 2022;10:950623. [PMID: 35874814 DOI: 10.3389/fcell.2022.950623] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]